JAMA ophthalmology最新文献

{"title":"Financial Return on Investment of Fellowship Training in Ophthalmology.","authors":"Daniel B Azzam,Abdullah W Mamdani,Leo Meller,Jenny Torres,Jeremiah Tao,Amar Joshi","doi":"10.1001/jamaophthalmol.2026.0901","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2026.0901","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"1 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147733385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ophthalmoplegia and Ptosis After Cancer Immunotherapy.","authors":"Veronika Yehezkeli,Payam Soltanzadeh,Federico G Velez","doi":"10.1001/jamaophthalmol.2026.0912","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2026.0912","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"427 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147733386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rosettelike and Whorllike Lesions in Enhanced S-Cone Syndrome.","authors":"Prithvi Ramtohul,Irmak Karaca,K Bailey Freund","doi":"10.1001/jamaophthalmol.2026.0945","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2026.0945","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"27 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147733380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brolucizumab in the Treatment of Proliferative Diabetic Retinopathy: The CONDOR Randomized Clinical Trial.","authors":"Sebastian Wolf,Youxin Chen,Xiaorong Li,Masahiko Shimura,Taiji Sakamoto,Charles C Wykoff,Andres Emanuelli,Hani Salehi-Had,Kang Yan,Lidija Kovacic,Yongsoo Kim","doi":"10.1001/jamaophthalmol.2026.1008","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2026.1008","url":null,"abstract":"ImportanceCONDOR (Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy) is a large-scale, company-sponsored randomized clinical trial to assess the unique 6-week (loading) and 12-week (maintenance) brolucizumab dosing regimen in proliferative diabetic retinopathy (PDR).ObjectiveTo assess the efficacy and safety of brolucizumab, 6 mg, compared with panretinal laser photocoagulation (PRP) in eyes with PDR.Design, Setting, and ParticipantsCONDOR is a 96-week, 2-arm, single-masked, multicenter, phase 3 randomized clinical trial conducted across 16 countries at 152 sites. Data were analyzed from December 4, 2020 (first participant first visit), to October 30, 2023 (cutoff date). Patients with diabetes and PDR diagnosis and no previous PRP treatment in the study eye were eligible for inclusion.InterventionPatients randomized to receive brolucizumab, 6 mg, received 3 loading doses every 6 weeks, followed by every 12 weeks, with the option from week 48 onward to extend the treatment interval by 6 weeks at a time up to 24 weeks based on disease activity. Patients randomized to PRP received treatment in 1 to 4 sessions up to week 12, followed by additional PRP treatment as needed.Main Outcomes and MeasuresThe primary outcome measure was change from baseline in best-corrected visual acuity (BCVA) at week 54. Secondary outcomes included change in DR progression, prevention of center-involved diabetic macular edema, change in Diabetic Retinopathy Severity Score levels, and safety.ResultsA total of 689 participants were randomized in a 1:1 ratio to brolucizumab, 6 mg (n = 347), or PRP (n = 342), and 572 randomized participants completed the week 54 visit. Mean (SD) patient age was 53.9 (11.39) years, 276 patients (40.1%) were female, and mean (SD) BCVA (letter score) at baseline was 77.1 (10.55) (Snellen equivalent, 20/32). Brolucizumab, 6 mg, was noninferior and superior to PRP for BCVA change at week 54 (least-squares mean [SE] change in letter score: 0.2 [0.72] vs -4.2 [0.73]; difference, 4.4; 95% CI, 2.4-6.4; P < .001). A higher proportion of patients receiving brolucizumab, 6 mg, had no PDR at week 54 vs patients receiving PRP (187 [63.6%] vs 65 [22.4%]; difference, 39.4; 95% CI, 32.0-46.8; P < .001). Ocular adverse events were reported in 119 patients (34.3%) and 168 patients (49.1%) in the brolucizumab, 6 mg, arm and PRP arm, respectively. The rate of intraocular inflammation, including retinal vasculitis, was 18 of 347 patients (5.2%) in the brolucizumab, 6 mg, arm and 2 of 342 patients (0.6%) in the PRP arm.Conclusions and RelevanceIn the CONDOR randomized clinical trial, brolucizumab was superior to PRP in preserving visual acuity and may be a viable treatment alternative to PRP monotherapy for patients with PDR.Trial RegistrationClinicalTrials.gov Identifier: NCT04278417.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"16 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147733383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Error in Byline and Figures.","authors":"","doi":"10.1001/jamaophthalmol.2026.1117","DOIUrl":"10.1001/jamaophthalmol.2026.1117","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":" ","pages":""},"PeriodicalIF":9.2,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13087896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147698657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cultured Human Corneal Endothelial Cell Injection for Endothelial Graft Failure After DSAEK.","authors":"Rintaro Ogino,Mariko Shirane,Taiyo Shijo,Osama Ibrahim,Yukari Yagi-Yaguchi,Daisuke Tomida,Takefumi Yamaguchi","doi":"10.1001/jamaophthalmol.2026.0812","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2026.0812","url":null,"abstract":"ImportanceEndothelial graft failure after Descemet stripping automated endothelial keratoplasty (DSAEK) is a clinically relevant problem, and the current standard treatment is repeat keratoplasty, which carries risks of surgery-related complications and depends on donor availability. Cultured human corneal endothelial cell (HCEC) therapy injection represents a potentially regenerative alternative; however, safety and outcomes for failed DSAEK grafts have not been reported.ObjectiveTo evaluate clinical outcomes of cultured HCEC therapy in eyes with endothelial graft failure after prior DSAEK.Design, Setting, and ParticipantsThis prospective case series included 4 consecutive eyes with DSAEK graft failure treated with cultured HCEC therapy at Tokyo Dental College Ichikawa General Hospital in 2025.ExposureIntracameral injection of cultured HCEC therapy for endothelial dysfunction after DSAEK.Main Outcomes and MeasuresBest-corrected visual acuity (BCVA, in logMAR [Snellen equivalent]), central corneal thickness (CCT), endothelial cell density (ECD), and intraocular pressure (IOP).ResultsA total of 4 eyes from 4 patients (mean [SD] age, 68.8 [9.3] years; 3 male [75%]) were included in this study. Mean (SD) BCVA improved from 1.93 (0.59) (Snellen, 20/1700) preoperatively to 0.46 (0.64) (Snellen, 20/60) at 3 months, with a mean change of -1.46 logMAR (15 Snellen lines; 95 CI, -1.87 to -1.05). Mean (SD) CCT changed from 900 (152) µm preoperatively to 641 (72) µm at 3 months with mean (SD) changes of -260 (73) µm (95% CI, -483 to -36 µm). Mean (SD) ECD could not be measured preoperatively because of severe corneal edema and was 1480 (989) cells/mm2 at 1 month and 2150 (723) cells/mm2 at 3 months. Mean (SD) IOP changed from 10 (2.1) mm Hg preoperatively to 13 (5.2) mm Hg at 3 months, with a mean (SD) change of +3.5 (2.1) mm Hg (95% CI, -7.6 to 14.6 mm Hg). Cystoid macular edema was observed in 2 eyes and was managed with topical diclofenac and sub-Tenon injections of triamcinolone acetonide. No other intraoperative and postoperative complications, including IOP elevation, infection, or graft detachment, were observed.Conclusions and RelevanceAlthough limited to 4 eyes without controls, these findings suggest that cultured HCECs transplantation may be a feasible option for eyes with DSAEK graft failure. Confirmation in larger, controlled studies with longer follow-up is warranted.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"66 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147695114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Metrics Assessing Surgical Success in Patients Undergoing Cataract Surgery.","authors":"Yang Li,Dustin D French,Azraa S Chaudhury,Sandeepkumar Gaddam,Chris A Andrews,Shikha Marwah,Adovich S Rivera,Xueqing Zhou,Charlesnika T Evans,Paul J Bryar,Joshua D Stein, ","doi":"10.1001/jamaophthalmol.2026.0845","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2026.0845","url":null,"abstract":"ImportanceAs health insurers, payers, and policymakers look to Merit-Based Incentive Payment System (MIPS) measures to judge eye care quality, compare surgeon performance, and make decisions about reimbursement, it is essential to understand the validity and generalizability of these metrics.ObjectiveTo assess the validity and generalizability of 2024 MIPS measure 191, Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery.Design, Setting, ParticipantsThis was a retrospective cohort study of patients who underwent at least 1 cataract surgery from 2010 through 2023 at any of 16 participating health systems in the Sight Outcomes Research Collaborative (SOURCE). The study assessed whether patient demographic characteristics and nonclinical and clinical factors were associated with achieving success, which MIPS measure 191 defines as a best recorded visual acuity of at least 20/40 within 90 days following cataract surgery. Data analysis was conducted from June 2024 to December 2025.ExposuresCataract surgery.Main Outcomes and MeasuresThe percentage of patients undergoing cataract surgery achieving success and the odds of surgical success were determined; for patients with 2 operative eyes, only the first eye surgery was assessed. Success rates were evaluated among all surgery recipients and separately among patients with no preexisting chronic ocular diseases as specified by the metric. Success rates were quantified using more stringent cutoffs and adjusting the follow-up duration. Logistic regression models assessed how nonbiological determinants of health and clinical factors influenced the odds of success.ResultsA total of 55 132 patients underwent cataract surgery (mean [SD] age, 70.3 [9.3] years; 32 240 [58.5%] female; 1973 [3.6%] Asian American; 7053 [12.8%] Black; 1993 [3.6%] Hispanic; 42 178 [76.5%] White [race and ethnicity were self-reported]). Among all patients undergoing surgery, 49 979 (90.7%) achieved surgical success. Excluding patients with ocular comorbidities (25 563 patients [46.4%]), 28 242 of 29 569 (95.5%) achieved surgical success. Living in the least (vs most) affluent community (odds ratio [OR], 0.81; 95% CI, 0.72-0.91), undergoing complex surgery (OR, 0.82; 95% CI, 0.75-0.89) or a combination of cataract with another intraocular surgery (OR, 0.32; 95% CI, 0.29-0.35), and having diabetes (OR, 0.90; 95% CI, 0.84-0.98) were associated with lower odds of surgical success.Conclusions and RelevanceIn this cohort study, most patients undergoing cataract surgery achieved success as defined by MIPS measure 191; however, the existing measure excluded nearly half of patients undergoing surgery, and older patients and Black patients were more likely to be excluded. Case-mix adjustment of patients' sociodemographic characteristics and clinical factors may be necessary to ensure fairness when comparing surgeons' performance.","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"194 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147695116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Treatment Response and 90-Day Vision in Microbial Keratitis.","authors":"Madeline K Weber,Leslie M Niziol,Mercy Pawar,Mason M Kipley,Pauline M Dmitriev,Farida E Hakim,Angela S Gupta,Sina Farsiu,N Venkatesh Prajna,Maria A Woodward","doi":"10.1001/jamaophthalmol.2026.0713","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2026.0713","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"22 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147695117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outer Retinal Disruption in a Young Male.","authors":"Rawan Kharouba,Seema Emami,Debra Anne Goldstein","doi":"10.1001/jamaophthalmol.2026.0807","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2026.0807","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"32 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147695115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Rise of Cultured Human Corneal Endothelial Cell Therapy.","authors":"Yilin Feng,Charles C Lin,Jennifer Rose-Nussbaumer","doi":"10.1001/jamaophthalmol.2026.0919","DOIUrl":"https://doi.org/10.1001/jamaophthalmol.2026.0919","url":null,"abstract":"","PeriodicalId":14518,"journal":{"name":"JAMA ophthalmology","volume":"61 1","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147695113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}